List of Excipients in Branded Drug DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC

Generic Drugs Containing DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	dorzolamide hydrochloride	50090-4882	BENZALKONIUM CHLORIDE
A-S Medication Solutions	dorzolamide hydrochloride	50090-4882	HYDROXYETHYL CELLULOSE
A-S Medication Solutions	dorzolamide hydrochloride	50090-4882	MANNITOL
A-S Medication Solutions	dorzolamide hydrochloride	50090-4882	SODIUM HYDROXIDE
A-S Medication Solutions	dorzolamide hydrochloride	50090-4882	TRISODIUM CITRATE DIHYDRATE
A-S Medication Solutions	dorzolamide hydrochloride	50090-4882	WATER

What are the Most Frequently-Used Excipients in DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC?

# Of NDCs	Excipient
2	BENZALKONIUM CHLORIDE
2	HYDROXYETHYL CELLULOSE
2	MANNITOL
1	NITROGEN
1	SODIUM CITRATE
2	SODIUM HYDROXIDE

Last updated: September 24, 2026

Executive summary: Dorzolamide hydrochloride ophthalmic is a mature, off-patent small-molecule glaucoma product with limited active-ingredient exclusivity but meaningful formulation and manufacturing opportunities. The commercial opportunity is concentrated in preservative-free delivery, low-irritation multidose packaging, unit-dose products, combination therapy, and cost-efficient sterile manufacturing. The incumbent 2% solution uses benzalkonium chloride, hydroxyethyl cellulose, mannitol, citrate buffer, sodium hydroxide, and water. A differentiated excipient strategy must improve ocular-surface tolerability without compromising dorzolamide solubility, sterility, container compatibility, or FDA substitutability.

Dorzolamide Hydrochloride Ophthalmic Excipient Strategy and Commercial Opportunities

What is dorzolamide hydrochloride ophthalmic?

Dorzolamide hydrochloride ophthalmic is a topical carbonic anhydrase inhibitor used to reduce elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The reference product, Trusopt, is a sterile 2% ophthalmic solution marketed by Merck. Dorzolamide is generally administered three times daily as monotherapy and twice daily when used with a topical beta blocker such as timolol.

Dorzolamide hydrochloride is a small molecule, not a biologic. Biosimilar regulation is therefore not applicable. Follow-on products are generally developed through the abbreviated new drug application, or ANDA, pathway, subject to pharmaceutical equivalence, bioequivalence where applicable, quality requirements, and any remaining listed-patent certifications.

The main formulation challenge is that dorzolamide hydrochloride requires an acidic aqueous environment for acceptable solubility and stability. The product also must remain comfortable on the ocular surface despite repeated administration.

What excipients are used in the reference dorzolamide ophthalmic solution?

The Trusopt formulation uses the following excipient classes:

Component	Function
Dorzolamide hydrochloride	Active carbonic anhydrase inhibitor
Hydroxyethyl cellulose	Viscosity modifier and residence-time enhancer
Mannitol	Tonicity adjustment and formulation stabilizer
Sodium citrate	Buffering agent
Sodium hydroxide	pH adjustment
Benzalkonium chloride	Antimicrobial preservative
Purified water	Vehicle

The labeled pH is approximately 5.5 to 5.9, and the product is adjusted to an ophthalmically acceptable osmolality range. The acidic pH supports drug solubility, while hydroxyethyl cellulose increases viscosity and may extend ocular residence time. Benzalkonium chloride, commonly called BAK, supplies multidose preservative protection but creates a potential tolerability issue in chronic glaucoma therapy (Merck & Co., 2023).

The reference excipient system is commercially important because it establishes the benchmark for generic equivalence. A reformulated product that changes preservative, viscosity, pH, container, or dosing format may be commercially differentiated but can face a more complex regulatory pathway than a conventional ANDA.

Which excipients create the largest commercial opportunity?

The highest-value excipient opportunities involve ocular-surface tolerability and preservative reduction.

Preservative-free formulations

Chronic exposure to BAK has been associated with ocular-surface irritation, tear-film disruption, epithelial toxicity, and worsening symptoms in some glaucoma patients. The risk is relevant for patients receiving multiple preserved eye drops over many years.

Potential preservative-free approaches include:

• Single-dose sterile vials.
• Multidose containers with antimicrobial barrier technology.
• One-way valve or airless dispensing systems.
• Preservative systems with lower ocular-surface burden.
• Alternative oxidative or ionic preservation systems, subject to compatibility and regulatory validation.

A unit-dose product removes BAK but increases packaging cost, fill-finish complexity, shipping volume, and administration waste. A preservative-free multidose system can offer a stronger commercial proposition if it maintains sterility through the labeled in-use period.

Alternative preservatives

Potential alternatives include polyquaternium-1, sodium perborate-derived systems, stabilized oxychloro complexes, and other ophthalmic preservative technologies. Each option must be evaluated for:

• Antimicrobial effectiveness.
• Dorzolamide chemical stability.
• Compatibility with the bottle, tip, seal, and closure.
• Ocular-surface tolerability.
• Extractables and leachables.
• Drop-size consistency.
• FDA acceptance of the changed formulation.

The presence of an alternative preservative does not automatically establish clinical superiority. Commercial claims generally require supporting tolerability or user-experience data.

Viscosity modifiers

Hydroxyethyl cellulose is a practical baseline excipient because it increases viscosity without requiring a gel-forming delivery system. Other candidates include hypromellose, carboxymethylcellulose, polyvinyl alcohol, carbomers, and selected poloxamers.

A higher-viscosity product may increase precorneal residence time and reduce drainage, but it can also cause blurred vision, sticky sensation, slower redispersion, or inconsistent drop delivery. The target is usually a modest increase in residence time rather than a high-viscosity gel.

The excipient strategy should control:

• Viscosity at room and refrigerated temperatures.
• Shear behavior during drop formation.
• Interaction with the bottle tip.
• Patient-perceived blur.
• Dose uniformity throughout the container.
• Compatibility with combination products.

Buffer and pH design

Dorzolamide hydrochloride is sensitive to the balance between solubility, comfort, and chemical stability. Citrate is used in the reference product, but phosphate, borate, acetate, or low-buffer-capacity systems may be assessed during development.

A lower buffer capacity can allow the formulation to move toward physiologic tear pH after instillation and may improve comfort. The tradeoff is reduced control of pH during storage and greater sensitivity to container interaction, carbon dioxide exposure, and manufacturing variation.

A viable development program should map:

1. Dorzolamide solubility across pH.
2. Degradation pathways across temperature and light exposure.
3. Buffer capacity after dilution with tears.
4. Osmolality and ocular comfort.
5. Container-closure interaction.
6. Stability after opening.

Tonicity agents

Mannitol is used in the reference product. Sodium chloride, glycerol, and other compatible tonicity agents may be considered, but substitutions can affect viscosity, comfort, osmolality, and preservative performance.

Tonicity should be optimized with pH rather than treated as an isolated variable. A formulation within a broad ophthalmic osmolality range may still produce discomfort if the buffer system and active concentration create a strong local sensation.

What formulations are protected or differentiated in dorzolamide ophthalmic products?

Formulation differentiation can arise from the following technical features:

Formulation area	Potential differentiation
Preservative system	BAK-free, low-BAK, alternative preservative, or preservative-free
Container	Unit-dose vial, multidose valve, airless pump, low-residual bottle
Viscosity	Controlled residence time with reduced blur
pH	Improved comfort while preserving solubility
Osmolality	Reduced stinging and better tear compatibility
Combination therapy	Dorzolamide-timolol in a single bottle
Packaging	Small drop size, ergonomic bottle, adherence-oriented design
Manufacturing	Improved sterile filtration, aseptic processing, or fill accuracy

A formulation patent may cover a narrow combination of active concentration, pH, buffer, preservative, viscosity agent, or container. A commercial product can also have freedom-to-operate exposure through manufacturing-process claims, device patents, or combination-product claims even after core dorzolamide patents expire.

Patentability is strongest where the formulation produces an unexpected technical effect, such as materially improved stability, preservative-free multidose sterility, reduced irritation, or superior drop uniformity. A simple substitution of mannitol, buffer, or viscosity agent is less likely to support a durable patent position without comparative data.

When did dorzolamide lose market exclusivity?

Dorzolamide ophthalmic is a mature generic product. The core U.S. exclusivity period for Trusopt has expired, and generic dorzolamide hydrochloride ophthalmic solutions have been marketed for many years.

The relevant regulatory history is:

Milestone	Status
Trusopt active ingredient	Dorzolamide hydrochloride
Dosage form	Sterile ophthalmic solution
Strength	2%
Reference sponsor	Merck
U.S. approval	1990s
Core small-molecule exclusivity	Expired
Generic pathway	ANDA
Biosimilar pathway	Not applicable
Current commercial position	Mature generic market

The main commercial barrier is no longer basic active-ingredient exclusivity. It is execution: sterile manufacturing, reliable supply, reimbursement, pharmacy substitution, preservative differentiation, and access to ophthalmology channels.

What is the Orange Book status of dorzolamide ophthalmic?

Dorzolamide ophthalmic is an Orange Book-listed small-molecule product category. Orange Book analysis should distinguish among:

• The reference listed drug.
• Approved generic dorzolamide products.
• Combination products containing dorzolamide and timolol.
• Any remaining listed patents or certifications associated with a specific reference product.
• Product-specific exclusivity or dispensing information.

Because the core product is mature, a new ANDA applicant generally faces lower patent risk than an applicant targeting a newly approved ophthalmic formulation. Risk can still arise from listed formulation patents, device patents, pediatric exclusivity, or product-specific regulatory protections.

An ANDA strategy should review the current FDA Orange Book entry and patent certification requirements immediately before filing. Historical expiration of core Trusopt patents does not eliminate the need to assess current listings for the exact dosage form and reference product (U.S. Food and Drug Administration, 2024a).

Are Paragraph IV challenges relevant to dorzolamide hydrochloride ophthalmic?

Paragraph IV litigation is primarily relevant when an ANDA applicant certifies that an Orange Book-listed patent is invalid, unenforceable, or not infringed. For a mature dorzolamide product, Paragraph IV risk is likely to be concentrated in later formulation, combination, or device patents rather than the original active-ingredient patent estate.

A generic sponsor can pursue:

• Paragraph III certification if a listed patent remains valid but has a defined expiry.
• Paragraph IV certification for an invalidity or non-infringement position.
• Section viii statement where the applicant omits a patented method of use.
• Conventional certification where no relevant patent remains listed.

The commercial value of a Paragraph IV strategy depends on whether the product can launch before other generic applicants and whether the patent claim covers the actual commercial formulation.

What patent litigation affects dorzolamide ophthalmic?

Dorzolamide has been involved historically in patent disputes associated with ophthalmic carbonic anhydrase inhibitors, Trusopt, and related products. The central patent risk has declined as the original exclusivity period expired and multiple generic products entered the market.

For current business planning, the relevant litigation questions are narrower:

1. Are any formulation or container patents listed against the selected reference product?
2. Does the proposed preservative-free system practice a third-party delivery claim?
3. Does a dorzolamide-timolol combination create separate patent exposure?
4. Are method-of-use claims directed to a dosing regimen or patient population?
5. Does the manufacturing process use a licensed sterile-fill or packaging technology?

No biosimilar litigation framework applies. No broad active-ingredient patent barrier is expected to block ordinary dorzolamide ophthalmic generic entry.

How strong is the dorzolamide ophthalmic patent estate?

The estate is weak for basic 2% dorzolamide solution entry but can be stronger for differentiated delivery systems.

Patent category	Relative risk
Original dorzolamide compound	Low
Basic 2% ophthalmic solution	Low
Standard buffer and tonicity system	Low to moderate
Preservative-free multidose packaging	Moderate to high
Combination with timolol	Moderate
Specialized delivery device	Moderate to high
Manufacturing process	Moderate
New method of use	Low to moderate

Patent strength will depend on claim construction, prior art, written description, enablement, and whether the technical benefit is demonstrated across the claimed formulation range.

A company seeking durable protection should prioritize a platform claim around preservative-free multidose sterility, container-closure performance, and measurable stability or tolerability benefits. A narrow excipient swap is less defensible as a standalone commercial moat.

What generic entry risks exist for dorzolamide ophthalmic?

Generic entry risk is high because:

• The product is an established small molecule.
• Multiple suppliers can manufacture aqueous ophthalmic solutions.
• The reference formulation uses conventional excipients.
• Therapeutic substitution is familiar to pharmacies and payers.
• The active ingredient does not require complex biologic characterization.
• Core exclusivity has expired.

The remaining barriers include sterile facility qualification, ophthalmic microbiological controls, regulatory inspection readiness, preservative-effectiveness testing, container qualification, and reliable supply of ophthalmic-grade components.

A low-cost standard product is likely to face rapid price competition. A differentiated product has better margin potential but may require clinical tolerability data, new-device validation, physician adoption, and payer justification.

Which commercial opportunities are available?

Preservative-free chronic glaucoma therapy

This is the clearest excipient-led opportunity. The target customers are patients with ocular-surface disease, patients using multiple topical therapies, and specialists seeking to reduce preservative exposure.

The product can be positioned through:

• Preservative-free unit-dose packaging.
• Preservative-free multidose delivery.
• Reduced drop volume.
• Lower irritation claims supported by clinical evidence.
• Combination therapy that reduces the number of daily instillations.

Dorzolamide-timolol fixed combination

A fixed combination can improve adherence by consolidating two active ingredients. The excipient program must address compatibility between dorzolamide hydrochloride and timolol maleate, preservative protection, pH, viscosity, and long-term stability.

Cosopt established the commercial precedent for this combination. Generic products compete primarily on price, but preservative-free packaging and improved tolerability can create a differentiated segment.

Contract manufacturing and regional supply

Dorzolamide ophthalmic is suitable for established sterile ophthalmic manufacturers with validated compounding, sterile filtration, aseptic filling, and ophthalmic packaging capabilities. Regional supply opportunities may arise where local procurement favors dependable availability over brand loyalty.

Manufacturing economics improve when the same platform supports dorzolamide, dorzolamide-timolol, timolol, brimonidine, or other aqueous ophthalmic products. The main constraint is avoiding cross-contamination and maintaining product-specific cleaning and validation controls.

Device-led differentiation

A bottle that delivers a smaller, consistent drop can reduce product waste and improve administration. This opportunity sits partly outside excipient strategy but directly affects formulation performance. Viscosity and surface tension must be optimized with the dispensing system.

Device patents and combination-product requirements can create a stronger commercial barrier than the active formulation alone.

How does dorzolamide compare with other glaucoma products?

Product	Main class	Key formulation issue	Differentiation opportunity
Dorzolamide	Carbonic anhydrase inhibitor	Acidic solution, repeated dosing, BAK exposure	Preservative-free delivery and fixed combination
Brinzolamide	Carbonic anhydrase inhibitor	Suspension behavior and shaking requirement	Clear solution, lower residue, improved comfort
Timolol	Beta blocker	Preservative exposure and systemic effects	Preservative-free and combination products
Brimonidine	Alpha-2 agonist	Ocular allergy and tolerability	Preservative reduction and dosing convenience
Latanoprost	Prostaglandin analog	Stability and preservative sensitivity	Preservative-free multidose systems

Dorzolamide’s advantage is solution-based delivery without the shaking requirements associated with some suspension products. Its disadvantages include three-times-daily dosing as monotherapy and the need to manage acidic pH and preservative exposure.

What FDA regulatory pathway applies?

A conventional generic 2% dorzolamide ophthalmic solution is generally pursued through an ANDA referencing the relevant FDA reference listed drug. The sponsor must demonstrate pharmaceutical equivalence and meet applicable quality, sterility, stability, container-closure, and labeling requirements.

A materially reformulated product may require a 505(b)(2) application if it cannot rely fully on the reference product’s safety and efficacy findings. This pathway may be appropriate for:

• A new preservative-free multidose system.
• A substantially different delivery device.
• A new concentration or dosing format.
• A new fixed combination.
• A formulation with a clinical tolerability claim.

The regulatory strategy should align the formulation ambition with the commercial objective. A conventional ANDA minimizes development burden but offers limited differentiation. A 505(b)(2) product can support stronger positioning but requires greater investment and may face more extensive clinical and regulatory review (U.S. Food and Drug Administration, 2024b).

What revenue exposure exists for dorzolamide products?

Dorzolamide revenue is exposed to generic price erosion, pharmacy substitution, tender competition, and concentration among sterile ophthalmic manufacturers. Brand-level revenue is less likely to come from the active ingredient alone than from:

• Fixed combinations.
• Preservative-free presentations.
• Specialty pharmacy access.
• Hospital and government tenders.
• Premium packaging.
• Supply reliability.
• Geographic markets with limited generic penetration.

A standard 2% BAK-preserved product is a volume business. A preservative-free or device-enabled product can support higher net pricing, but only if the product demonstrates patient or prescriber value and avoids excessive packaging cost.

What geographic coverage matters?

The United States is governed by FDA approval, Orange Book listings, and ANDA or 505(b)(2) requirements. Europe follows national or centralized procedures depending on the product and legal basis, with additional requirements under the European Pharmacopoeia and applicable national substitution rules. Other markets may accept mature generic ophthalmic products through abbreviated or local registration pathways.

Geographic patent risk is jurisdiction-specific. U.S. patent expiry does not establish freedom to launch in Europe, Canada, Japan, China, or emerging markets. Companies should separately assess:

• Active patents.
• Regulatory data protection.
• Local reference-product requirements.
• Trademark and trade-dress rights.
• Device patents.
• Manufacturing and import rules.
• Local pharmacopoeial standards.

Key Takeaways

• Dorzolamide hydrochloride ophthalmic is a mature, off-patent small-molecule product.
• The reference formulation uses hydroxyethyl cellulose, mannitol, citrate, sodium hydroxide, BAK, and water.
• The strongest commercial opportunity is preservative-free or low-irritation delivery for chronic glaucoma treatment.
• A conventional ANDA offers the lowest regulatory cost but faces substantial price competition.
• Preservative-free multidose packaging, unit-dose products, fixed dorzolamide-timolol combinations, and device-led delivery provide stronger differentiation.
• Formulation patents are more commercially relevant than expired compound patents.
• The main operational barriers are sterile manufacturing, container-closure performance, antimicrobial protection, stability, and reliable supply.
• Biosimilar risk is not relevant because dorzolamide is a small molecule.
• A 505(b)(2) strategy may support a differentiated delivery system but carries greater development and regulatory expense.

FAQs

Can BAK be removed from dorzolamide ophthalmic without changing the active ingredient?

Yes. BAK can be removed through unit-dose packaging or replaced with a multidose preservation and dispensing system. The change requires new sterility, antimicrobial effectiveness, stability, container-closure, and regulatory support.

Is dorzolamide hydrochloride ophthalmic a good candidate for a preservative-free generic?

Yes. Its chronic dosing pattern and ocular-surface exposure create a reasonable commercial basis for preservative-free development. The economic case is strongest when the product uses efficient multidose packaging rather than high-cost single-use vials.

Does hydroxyethyl cellulose improve dorzolamide ophthalmic performance?

Hydroxyethyl cellulose increases viscosity and may extend ocular residence time. Excessive viscosity can cause blur, discomfort, and inconsistent drop delivery, so the excipient level must be optimized against the dispensing container.

Can a new dorzolamide formulation receive new patent protection?

Potentially. Protection is more credible for a formulation that demonstrates an unexpected technical result, such as preserved multidose sterility without BAK, improved stability, reduced irritation, or superior drop uniformity. Routine excipient substitution is less likely to provide strong protection.

Is dorzolamide-timolol more commercially attractive than dorzolamide alone?

In many markets, yes. The fixed combination can reduce administration burden and improve adherence. Its commercial value depends on pricing, competition from generic Cosopt-equivalent products, preservative profile, and the ability to differentiate the delivery system.

References

1. Merck & Co. (2023). Trusopt (dorzolamide hydrochloride ophthalmic solution) prescribing information. U.S. Food and Drug Administration.

2. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024b). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-resources/applications-covered-section-505b2

4. European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe.

5. Baudouin, C., Labbe, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334. https://doi.org/10.1016/j.preteyeres.2010.03.001